Nature Communications (Oct 2018)

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

  • Ricardo A. P. Pádua,
  • Yizhi Sun,
  • Ingrid Marko,
  • Warintra Pitsawong,
  • John B. Stiller,
  • Renee Otten,
  • Dorothee Kern

DOI
https://doi.org/10.1038/s41467-018-06814-w
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 14

Abstract

Read online

The protein tyrosine phosphatase SHP2 is a key regulator of cell cycle control. Here the authors combine NMR measurements and X-ray crystallography and show that wild-type SHP2 dynamically exchanges between a closed inactive conformation and an open activated form and that the oncogenic E76K mutation shifts the equilibrium to the open state, which is reversed by binding of the allosteric inhibitor SHP099.